AMARIN CORPORATION PLC - AMERICAN DEPOSITARY SHARE

Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiology’s 70th Annual Scientific Session

04 May 2021 06:00:01 By Nasdaq GlobeNewswire

Amarin Reports First Quarter 2021 Financial Results and Provides Business Update

29 Apr 2021 05:10:00 By Nasdaq GlobeNewswire

Amarin Announces Planned Retirement of Joseph T. Kennedy, EVP, General Counsel

29 Apr 2021 05:00:00 By Nasdaq GlobeNewswire

Amarin Receives Great Britain Marketing Authorization for VAZKEPA from the Medicines and Healthcare Products Regulatory Agency (MHRA) 1,2

22 Apr 2021 09:53:02 By Nasdaq GlobeNewswire

Amarin to Report First Quarter Results and Host Conference Call on April 29, 2021

20 Apr 2021 05:05:00 By Nasdaq GlobeNewswire

VASCEPA® (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021

17 Apr 2021 08:50:00 By Nasdaq GlobeNewswire

Amarin Announces CEO Succession Plan

12 Apr 2021 15:30:00 By Nasdaq GlobeNewswire

Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication

06 Apr 2021 05:05:00 By Nasdaq GlobeNewswire

Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk

30 Mar 2021 05:24:23 By Nasdaq GlobeNewswire

Fifteen Medical Societies Now Recommend Icosapent Ethyl to Reduce Cardiovascular Risk, Further Supporting that VASCEPA® is Rapidly Becoming a New Standard of Care

29 Mar 2021 06:00:00 By Nasdaq GlobeNewswire